🇺🇸 FDA
Patent

US 7592343

Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors

granted A61KA61K31/501A61P

Quick answer

US patent 7592343 (Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors) held by Xenon Pharmaceuticals Inc. expires Mon Sep 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Xenon Pharmaceuticals Inc.
Grant date
Tue Sep 22 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/501, A61P, A61P1/06, A61P1/16